Adam Boxer

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial
    Adam L Boxer
    Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA, USA Electronic address
    Lancet Neurol 13:676-85. 2014
  2. pmc Oculomotor function in frontotemporal lobar degeneration, related disorders and Alzheimer's disease
    Siobhan Garbutt
    Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA 94143 1207, USA
    Brain 131:1268-81. 2008
  3. pmc The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier)
    Adam L Boxer
    Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA, USA
    Alzheimers Dement 9:189-98. 2013
  4. pmc Frontotemporal degeneration, the next therapeutic frontier: molecules and animal models for frontotemporal degeneration drug development
    Adam L Boxer
    Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA, USA
    Alzheimers Dement 9:176-88. 2013
  5. pmc Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial
    Adam L Boxer
    Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA, USA
    Lancet Neurol 12:149-56. 2013
  6. pmc Multicenter validation of a bedside antisaccade task as a measure of executive function
    J Hellmuth
    Department of Neurology, Memory and Aging Center, University of California, San Francisco, USA
    Neurology 78:1824-31. 2012
  7. pmc Saccade abnormalities in autopsy-confirmed frontotemporal lobar degeneration and Alzheimer disease
    Adam L Boxer
    Memory and Aging Center, Department of Neurology, University of California San Francisco, CA 94143 1207, USA
    Arch Neurol 69:509-17. 2012
  8. pmc Atypical, slowly progressive behavioural variant frontotemporal dementia associated with C9ORF72 hexanucleotide expansion
    Baber K Khan
    Department of Neurology, University of California San Francisco, San Francisco, CA, USA
    J Neurol Neurosurg Psychiatry 83:358-64. 2012
  9. pmc Medial versus lateral frontal lobe contributions to voluntary saccade control as revealed by the study of patients with frontal lobe degeneration
    Adam L Boxer
    Department of Neurology, Memory and Aging Center, University of California, San Francisco, California 94143 1207, USA
    J Neurosci 26:6354-63. 2006
  10. ncbi Amyloid imaging in distinguishing atypical prion disease from Alzheimer disease
    A L Boxer
    Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA 94143 1207, USA
    Neurology 69:283-90. 2007

Research Grants

Detail Information

Publications23

  1. pmc Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial
    Adam L Boxer
    Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA, USA Electronic address
    Lancet Neurol 13:676-85. 2014
    ..Because progressive supranuclear palsy (PSP) is linked to tau pathology, davunetide could be a treatment for PSP. We assessed the safety and efficacy of davunetide in patients with PSP...
  2. pmc Oculomotor function in frontotemporal lobar degeneration, related disorders and Alzheimer's disease
    Siobhan Garbutt
    Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA 94143 1207, USA
    Brain 131:1268-81. 2008
    ..These data suggest that oculomotor assessment may aid in the diagnosis of FTLD and related disorders...
  3. pmc The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier)
    Adam L Boxer
    Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA, USA
    Alzheimers Dement 9:189-98. 2013
    ..We conclude that FTD research has reached sufficient maturity to pursue clinical development of specific FTD therapies...
  4. pmc Frontotemporal degeneration, the next therapeutic frontier: molecules and animal models for frontotemporal degeneration drug development
    Adam L Boxer
    Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA, USA
    Alzheimers Dement 9:176-88. 2013
    ....
  5. pmc Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial
    Adam L Boxer
    Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA, USA
    Lancet Neurol 12:149-56. 2013
    ..A previous 26-week open-label study suggested a transient, modest benefit on neuropsychiatric symptoms as measured by the neuropsychiatric inventory (NPI). We aimed to determine whether memantine is an effective treatment for FTD...
  6. pmc Multicenter validation of a bedside antisaccade task as a measure of executive function
    J Hellmuth
    Department of Neurology, Memory and Aging Center, University of California, San Francisco, USA
    Neurology 78:1824-31. 2012
    ..To create and validate a simple, standardized version of the antisaccade (AS) task that requires no specialized equipment for use as a measure of executive function in multicenter clinical studies...
  7. pmc Saccade abnormalities in autopsy-confirmed frontotemporal lobar degeneration and Alzheimer disease
    Adam L Boxer
    Memory and Aging Center, Department of Neurology, University of California San Francisco, CA 94143 1207, USA
    Arch Neurol 69:509-17. 2012
    ..Deficits in the generation and control of saccades have been described in clinically defined frontotemporal dementia (FTD) and Alzheimer disease (AD)...
  8. pmc Atypical, slowly progressive behavioural variant frontotemporal dementia associated with C9ORF72 hexanucleotide expansion
    Baber K Khan
    Department of Neurology, University of California San Francisco, San Francisco, CA, USA
    J Neurol Neurosurg Psychiatry 83:358-64. 2012
    ..Here, two patients with bvFTD-SP with chromosome 9 open reading frame 72 (C9ORF72) hexanucleotide expansions are described...
  9. pmc Medial versus lateral frontal lobe contributions to voluntary saccade control as revealed by the study of patients with frontal lobe degeneration
    Adam L Boxer
    Department of Neurology, Memory and Aging Center, University of California, San Francisco, California 94143 1207, USA
    J Neurosci 26:6354-63. 2006
    ....
  10. ncbi Amyloid imaging in distinguishing atypical prion disease from Alzheimer disease
    A L Boxer
    Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA 94143 1207, USA
    Neurology 69:283-90. 2007
    ..To compare the in vivo uptake of two amyloid-binding PET agents, PIB and FDDNP, in human subjects with a prion protein (PrP) gene (PRNP) mutation that produces a clinical syndrome similar to Alzheimer disease (AD)...
  11. ncbi Frontotemporal dementia treatment: current symptomatic therapies and implications of recent genetic, biochemical, and neuroimaging studies
    Adam L Boxer
    Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA 94143 1207, USA
    Alzheimer Dis Assoc Disord 21:S79-87. 2007
    ..In addition, the implications of new genetic and neuropathologic information about FTD for the design of future clinical trials and the eventual development of FTD-specific disease-modifying treatments are discussed...
  12. ncbi Patterns of brain atrophy that differentiate corticobasal degeneration syndrome from progressive supranuclear palsy
    Adam L Boxer
    Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA 94143 1207, USA
    Arch Neurol 63:81-6. 2006
    ..Progressive brain atrophy is associated with the corticobasal degeneration syndrome (CBDS) and progressive supranuclear palsy (PSP). Regional differences in brain atrophy may reflect the clinical features of disease...
  13. pmc An open-label study of memantine treatment in 3 subtypes of frontotemporal lobar degeneration
    Adam L Boxer
    Memory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA 94143 1207, USA
    Alzheimer Dis Assoc Disord 23:211-7. 2009
    ..Memantine was well-tolerated in these subjects. Future placebo-controlled trials of memantine in FTLD are warranted and may have greater power to detect behavioral and cognitive effects if focused on the FTD and SD clinical syndromes...
  14. pmc Clinical, neuroimaging and neuropathological features of a new chromosome 9p-linked FTD-ALS family
    Adam L Boxer
    UCSF Memory and Aging Center, University of California San Francisco, CA 94143, USA
    J Neurol Neurosurg Psychiatry 82:196-203. 2011
    ..Previous studies have identified a region on chromosome 9p that is associated with FTD and ALS...
  15. pmc Clinical-neuroimaging characteristics of dysexecutive mild cognitive impairment
    Judy Pa
    Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA 94117, USA
    Ann Neurol 65:414-23. 2009
    ..The goal of the study was to compare clinical and neuroimaging characteristics of two single-domain MCI subgroups: amnestic MCI and dysexecutive MCI...
  16. pmc Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial
    Robert C Green
    Department of Neurology, Boston University School of Medicine, 72 E Concord St, L 320, Boston, MA 02118, USA
    JAMA 302:2557-64. 2009
    ..Tarenflurbil, a selective Abeta(42)-lowering agent, demonstrated encouraging results on cognitive and functional outcomes among mildly affected patients in an earlier phase 2 trial...
  17. ncbi Executive dysfunction in hyperhomocystinemia responds to homocysteine-lowering treatment
    A L Boxer
    Memory and Aging Center, Department of Neurology, UCSF, San Francisco, CA 94143 1207, USA
    Neurology 64:1431-4. 2005
    ..These findings suggest that homocysteine-related cognitive impairment may be partially reversible...
  18. pmc Focal right inferotemporal atrophy in AD with disproportionate visual constructive impairment
    A L Boxer
    Memory and Aging Center, Department of Neurology, University of California at San Francisco, 94143 1207, USA
    Neurology 61:1485-91. 2003
    ..To explore the structural neuroimaging correlates of visual constructive impairment in patients with mild to moderate Alzheimer disease (AD)...
  19. pmc Demographic and neuropsychiatric factors associated with off-label medication use in frontotemporal dementia and Alzheimer's disease
    Maria Carmela Tartaglia
    Tanz Centre for Research in Neurodegenerative Disease, University of Toronto, Toronto, ON Department of Neurology, Memory and Aging Center Department of Psychiatry, University of California, San Francisco Stanford Geriatric Education Center, Stanford University School of Medicine, Palo Alto, CA
    Alzheimer Dis Assoc Disord 28:182-9. 2014
    ..We compared the use of cognitive and psychiatric medications in FTD and AD and evaluated the relationship between neuropsychiatric symptoms and medication use...
  20. pmc Deformation-based morphometry reveals brain atrophy in frontotemporal dementia
    Valerie A Cardenas
    Magnetic Resonance Unit, San Francisco Veterans Affairs Medical Center, CA 94121, USA
    Arch Neurol 64:873-7. 2007
    ..To compare deformation-based maps of local anatomical size between subjects with frontotemporal dementia (FTD) and healthy subjects to identify regions of the brain involved in FTD...
  21. ncbi Clinical features of frontotemporal dementia
    Adam L Boxer
    Memory and Aging Center, Department of Neurology, UCSF, San Francisco, California 94143 1207, USA
    Alzheimer Dis Assoc Disord 19:S3-6. 2005
    ....
  22. ncbi Clinical and neuropsychological features of corticobasal degeneration
    Nataliya Belfor
    University of California San Francisco, Memory and Aging Center, 350 Parnassus Avenue, Suite 705, 94143, USA
    Mech Ageing Dev 127:203-7. 2006
    ..Increasing awareness of this disorder has led to the realization that specific cognitive and imaging changes are common with CBD degeneration and that these changes help with clinical diagnosis...
  23. ncbi Cinguloparietal atrophy distinguishes Alzheimer disease from semantic dementia
    Adam L Boxer
    Memory and Aging Center and the Department of Neurology, University of California at San Francisco, 94143, USA
    Arch Neurol 60:949-56. 2003
    ..Progressive brain atrophy is associated with Alzheimer disease (AD) and other dementias. Regional differences in brain atrophy may reflect clinical features of disease...

Research Grants4

  1. Eye Movement Control in Normal Elderly and MCI
    Adam Boxer; Fiscal Year: 2009
    ..The data generated from this project will provide a new test to physicians that they can use during a patient visit to help decide who is at greatest risk for dementia and potentially who may benefit from such early treatment. ..
  2. Eye Movement Control in Normal Elderly and MCI
    Adam L Boxer; Fiscal Year: 2010
    ..The data generated from this project will provide a new test to physicians that they can use during a patient visit to help decide who is at greatest risk for dementia and potentially who may benefit from such early treatment. ..
  3. Four Repeat Tauopathy Neuroimaging Initiative
    Adam L Boxer; Fiscal Year: 2010
    ..The data generated from this project will allow researchers to design better clinical trials to test the efficacy of new tau- directed drugs in humans. ..